Becton, Dickinson and Company (BD) is engaged principally in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences.
BD Medical produces a portfolio of medical devices that are used in a wide range of healthcare settings. They include safety-engineered injection, infusion and surgery products. BD Medical’s principal product lines include needles, syringes and intravenous (IV) catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; regional anaesthesia needles and trays; sharps disposal containers; and home healthcare products. The primary markets served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; public health agencies; pharmaceutical companies; and healthcare workers. BD Diagnostics provides products for the collection and transport of diagnostic specimens and instrumentation for analysis across a broad range of infectious disease testing, including healthcare-associated infections (HAIs). BD Diagnostics’ principal products and services include integrated systems for specimen collection; safety-engineered collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually-transmitted diseases and HAIs; micro-organism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screenings; and rapid diagnostic assays. BD Diagnostics serves hospitals, laboratories and clinics; reference laboratories; blood banks; healthcare workers; patients; physicians’ office practices; and industrial microbiology laboratories. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. BD Biosciences’ principal product lines include fluorescence activated cell sorters and analysers; cell imaging systems, monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; cell culture media supplements for biopharmaceutical manufacturing; and diagnostic assays. The primary markets served by BD Biosciences are research and clinical laboratories; hospitals and transplant centres; blood banks; and biotechnology and pharmaceutical companies. BD’s products are manufactured and sold worldwide. The company has manufacturing operations outside the US in Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Mexico, Pakistan, Singapore, South Korea, Spain, Sweden and the UK.
The BD Medical Device Company Report provides a full review of the company's medical device activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures and litigation. Sections are also included on products, corporate strategy and R&D.
Whatever your interest or involvement, evaluating the performance, success, failures and developments of medical companies is critical. Espicom’s Medical Device Company Reports have been regularly published for over 20 years, and these critically acclaimed and respected management reports provide a complete review of leading players in the field.
Evaluate competitive threats Maximise product and market opportunities Identify collaborators and strategic partners Understand the operating market environment Benchmark your performance against competitors Coverage Overview
Key contact information Introduction to BD and its current activities Summary of its financial performance Key recent events in an “at a glance” format Strategic Focus
The company’s aims and its areas of focus Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available) Table providing in-depth five-year financial analysis Employee data, including breakdown by company division and geographic location Product Overview
Core product areas, key brands, product approvals and launches Identifies the company’s major competitors Research and Development
How much has been invested in R&D? Where is the research based? What alliances and agreements does BD have and with whom? Manufacturing and Distribution
Identifying the company’s manufacturing locations Sales and marketing facilities Agreements
With whom has BD reached agreements and what do they involve? Key contracts awarded Mergers and Acquisitions Minority Divestments Litigation Key Corporate Events
Table Of Contents
Becton-Dickinson Medical Device Company Intelligence Report OVERVIEW 2 STRATEGIC FOCUS 4 Espicom View 4 FINANCIAL REVIEW 5 Fiscal Year 2012 Financial Results 5 BD Medical 8 BD Diagnostics 8 Biosciences Segment 9 Five-Year Financial Data 10 Outlook 11 Employees 11 PRODUCTS 12 BD Medical 12 Medical Surgical Systems 13 Pharmaceutical Systems 14 Diabetes Care 14 BD Medical Product Updates 14 BD Diagnostics 16 Preanalytical Systems 17 Diagnostic Systems 17 BD Diagnostics - TriPath Products 17 BD Diagnostics - Infectious Disease 17 BD Diagnostic Product Updates 18 RESEARCH AND DEVELOPMENT 20 Research Establishments 20 RandD Expenditure 20 RandD Projects 20 BD Max Development 20 Juvenile Diabetes Research Foundation 20 MANUFACTURING AND DISTRIBUTION 22 Manufacturing 22 Distribution 22 AGREEMENTS 23 Asuragen 23 FIND 23 SDIX 24 Biodiversity 24 Lab21 24 Diagenode 24 MERGERS AND ACQUISITIONS 25 Cato Software Solutions 25 Safety Syringes 25 Kiestra Lab Automation 25 Carmel Pharma 25 DIVESTITURES 26 Discovery Labware Unit 26 LITIGATION 27 Hologic 27 Retractable Technologies 27 KEY CORPORATE EVENTS 28
List of Tables
Recent Key Events 3 Fiscal Year 2012 Financial Results 5 BD - Annual Financial Results, 2008-2012 5 BD - Annual Revenues by Business Segment and Geographic Area, 2009-2012 6 BD - Annual Revenues and Operating Income by Business Segment, 2008-2012 7 BD Medical - Annual Revenue by Unit and Geographic Area, 2009-2012 8 BD Diagnostics - Annual Revenue by Unit and Geographic Area, 2009-2012 8 BD Biosciences - Annual Revenue by Unit and Geographic Area, 2009-2012 9 BD - Five-Year Financial Summary 10 BD Employees, 2008-2012 11 Medical Surgical Systems Key Product Areas 13 Preanalytical Systems Key Product Areas 17 BD Diagnostics - Planned Product Launches 19 BD - RandD Expenses, 2008-2012 20 Agreements Summary 23 Mergers and Acquisitions Summary 25
List of Charts
BD - Annual Sales and Operating Income, 2008-2012 5 BD - Annual Revenues by Geographic Area, 2009-2012 6 BD- Annual Sales by Business Segment, 2008-2012 7 BD Medical - Annual Sales by Product Area, 2009-2012 13 BD Diagnostics - Annual Sales by Product Area, 2009-2012 16